DURHAM, N.C., June 13, 2013 (GLOBE NEWSWIRE) -- In conjunction with the U.S. Food and Drug Administration's (FDA) June 14th Public Meeting on HIV Patient-Focused Drug Development and HIV Cure Research, leading HIV researchers and Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today highlighted the role of immunotherapy in potential HIV eradication studies.